

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Not applicable	<i>In vitro</i> and mouse studies identified a compound that could be useful for treating AD. In cultured cells expressing amyloid- β (A β) precursor protein (APP), the compound upregulated α -secretase and inhibited β -amyloid (A β) secretion compared with vehicle control. In a mouse model of AD, i.v. delivery of an analog of the compound significantly reduced cerebral A β levels compared with delivery of vehicle control ($p < 0.0001$). Next steps include testing the compound's oral activity and measuring its ability to prevent or delay the formation of A β plaques in transgenic mouse models of AD. SciBX 3(27); doi:10.1038/scibx.2010.833 Published online July 15, 2010	Patent status undisclosed; licensing information available from the Cleveland Clinic Contact: Jonathan Smith, Cleveland Clinic, Cleveland, Ohio e-mail: smithj4@ccf.org Contact: Neil Veloso, same affiliation as above e-mail: veloson@ccf.org	Chakrabarti, E. <i>et al. J. Med. Chem.</i> ; published online June 22, 2010; doi:10.1021/jm100308g Contact: Jonathan D. Smith, Cleveland Clinic, Cleveland, Ohio e-mail: smithj4@ccf.org Contact: Gregory P. Tochtrop, Case Western Reserve University, Cleveland, Ohio e-mail: tochtrop@case.edu